Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-25 @ 3:30 AM
NCT ID:
NCT03808805
Eligibility Criteria:
Inclusion Criteria:
* Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis)
* and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months
* and suffering of persistent aquagenic pruritus
* and with a pruritus intensity on Analogic Visual Scale \>5/10
* patients who gave their written consent for participation in the study
Exclusion Criteria:
* patients with a physical or psychological disability to sign the consent form
* patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin
* patients already included in another therapeutic protocol
* patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo
* patients already on anti-anxiety and / or anti-depressant treatment
* patients with absolute contraindications to the use of Aprepitant or Hydroxyzine
* hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients
* lactose intolerance
* pregnant or lactating women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03808805
Study Brief:
Protocol Section:
NCT03808805